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Objectives:  The  French  ENT Society  (SFORL)  created  a workgroup  to  draw  up guidelines  for  the  manage-
ment  of  immunodeﬁcient  patients  with  head  and  neck  cancer  of cutaneous  origin.  The  present  guidelines
cover  diagnostic  and therapeutic  management  and  prevention  of head  and  neck  cancer  of  cutaneous
origin  in immunodeﬁcient  patients,  and  in particular  in transplant  patients  and  those  with  HIV  infection.
Materials  and methods:  The  present  guidelines  were  based  on  a  critical  multidisciplinary  reading  of  the
literature.  Immunosuppression  and  its varieties  are  deﬁned.  The  usual  risk  factors  for skin  cancer  and
those  speciﬁc  to  immunodeﬁciency  are  presented.  The  prevention,  assessment  and  management  of cuta-
neous  carcinoma,  melanoma,  Kaposi’s  sarcoma  and  lymphoma  are  dealt  with.  The  level  of evidence  of
the source  studies  was  assessed  so  as  to  grade  the  various  guidelines.  When  need be,  expert  opinions  are
put forward.
Results: Immunodeﬁcient  patients  are  at  higher  risk  of  head  and  neck  skin  tumors.  The  level  of  risk
depends  on the  type  of  deﬁciency;  there  is an especially  high  risk  of  squamous  cell carcinoma  in transplant
patients  and  of  Kaposi’s  sarcoma  in  HIV-positive  subjects.  Various  viruses  are  associated  with  skin  cancers.
Skin  tumors  are  often  evolutive  in case  of  immunodeﬁciency,  requiring  rapid  treatment.  Management  is
generally the same  as  in  immunocompetent  subjects  and  should  be discussed  in  a  multidisciplinary  team
meeting.  Immunosuppression  may  need  to be modulated.  In  organ  transplant  patients,  the  only  class  of
immunosuppressants  with  proven  antitumoral  efﬁcacy  are  mTOR  inhibitors,  particularly  in  cutaneous
squamous  cell  carcinoma.  The  rhythm  of clinical  surveillance  should  be  adapted  according  to the  risk  of
recurrence.  Preventive  measures  should  be undertaken.
Conclusion: Skin  cancers  in immunodeﬁciency  are  highly  evolutive,  requiring  the  earliest  possible  treat-
ment.  Immunosuppression  may  need modulating.  As  the risk  of  recurrence  may  be elevated,  careful
surveillance  should  be implemented.  Preventive  measures  should  also  be  undertaken.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.. IntroductionThe elevated risk of certain forms of cancer in case of immu-
odeﬁciency illustrates the importance of the immune system in
ontrolling their development [1,2] (level of evidence 2). Various
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ttp://dx.doi.org/10.1016/j.anorl.2014.02.002viruses, particularly HPV, HHV-8, EBV and polyomaviruses, are
implicated in skin cancer in immunodeﬁcient subjects. The increas-
ing life expectancy of immunodeﬁcient subjects and the increasing
frequency of transplantation entail an increasing incidence of can-
cer.The present guidelines concern the management of head and
neck tumor of cutaneous origin in transplant and HIV-infected
patients. The levels of evidence and grades employed are those
deﬁned by the French HAS health authority. The guidelines are
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ased on a detailed review of the literature by experts from var-
ous ﬁelds: ENT, nephrology, immunology and dermatology. They
ave been checked by several ENT and dermatology specialists.
.1. Transplant patients
Transplant patients mainly show T- and associated B-cell immu-
odeﬁciency. Anti-calcineurin inhibitors, which form a major
omponent of maintenance immunosuppression, are implicated
n the onset and dissemination of tumors [3] (level of evi-
ence 1). The increasing lifespan of grafts and age of patients
ccount for the increased incidence of cancer following trans-
lantation. Within some 15 years, cancer can be expected to
e the main cause of death following kidney transplanta-
ion.
The most frequent form of tumor following transplantation is
kin cancer, 95% of which is represented by squamous cell carci-
oma. Risk of squamous cell carcinoma is elevated 100-fold and
isk of basal cell carcinoma and of Kaposi sarcoma about 10-fold;
erkel-cell carcinoma, cutaneous lymphoma and melanoma, are
ikewise more frequent following transplantation.
.2. HIV-positive subjects
HIV-positive subjects show a 3.5-fold higher relative risk of can-
er than the general population [4] (level of evidence 2). The most
requent cancers are those classifying HIV infection as AIDS (39%),
lthough frequency has diminished with the advent of powerful
ntiretroviral therapies (ART). Elevated viral load is a risk factor.
Risk of skin cancer as a whole is elevated. There is a high risk of
aposi sarcoma, Merkel-cell carcinoma and sebaceous carcinoma.
here is also an increased risk of skin carcinoma, melanoma and
utaneous lymphoma. Unlike in transplant patients, basal cell car-
inoma is more frequently implicated than cutaneous squamous
ell carcinoma. Other factors than CD4 count and viral load seem
o be implicated, and HIV-positive subjects should be kept under
urveillance even at non-advanced stages.
.3. Risk factors
Virological risk factors include HPV (associated with squamous
ell carcinoma), HHV-8 (associated with Kaposi sarcoma), EBV
associated with certain skin lymphomas) and polyomavirus (asso-
iated with Merkel-cell carcinoma). Sun exposure [5] (level of
vidence 1) and clear phototype [5,6] (level of evidence 1–3) are
ajor risk factors for skin carcinoma and melanoma. Seventy per-
ent of transplant patients with history of skin cancer experience
ecurrence [6] (level of evidence 2).
Factors speciﬁc to transplant patients include gender (male), age
advanced) and interval since transplantation [7] (level of evidence
). Skin carcinoma is also associated with a count of > 50 actinic
eratoses [5] (level of evidence 3).
. Prevention
.1. Primary prevention of skin tumors associated with sun
xposure
Guideline 1
Patients should be informed of the increased risk of skincancer. Primary prevention consists in avoiding sunlight at
high-risk times of day, wearing protective clothing and using
sunscreen (Grade A).y, Head and Neck diseases 131 (2014) 121–129
2.2. Secondary prevention
Secondary prevention consists in early screening of skin tumor,
based on self-examination, dermatologic surveillance consulta-
tions, treatment of precancerous lesions and, in transplant patients
with multiple tumor, reduced immunosuppression or introduction
of retinoids.
3. Management of cutaneous squamous cell carcinoma
(CSCC) precursors
3.1. Actinic keratosis
In immunodeﬁcient subjects, evolution of actinic keratosis is
accelerated and more frequently toward squamous cell carcinoma
[5] (level of evidence 3).
Guideline 2
In case of thick actinic keratosis liable to malignant
transformation, surgical resection is recommended (Expert
consensus).
In case of non-inﬁltrated, single or sparse actinic keratosis,
cryotherapy is generally recommended. In case of multiple ker-
atoses, local 5-ﬂuoro-uracile (Grade B), diclofenac (Grade A) or
photodynamic therapy (PDT) may  be considered (Grade B).
3.2. In situ cutaneous squamous cell carcinoma (Bowen’s disease)
The clinical aspect comprises a sharply deﬁned erythematous
scaly plaque. Histology shows that about one-third of cases of
Bowen’s disease are focally invasive, especially in large carcinomas
[8] (level of evidence 3).
Guideline 3
Treatment should not be delayed, due to risk of evolution
toward an invasive tumor, and should be surgical (Grade B).
Topical 5-FU (once daily for 4 weeks) is the only second-line
treatment authorized in immunodeﬁcient patients in France.
Post-treatment clinical control is mandatory (Grade C).
4. Invasive CSCC
4.1. Indications for biopsy
Guideline 4
Any suspect squamous cell carcinoma should be biopsied
if clinical diagnosis is uncertain or non-surgical treatment is
planned, or to conﬁrm diagnosis ahead of complex surgery
(Expert consensus).
4.2. Histology
4.3. Prognostic classiﬁcation of inﬁltrating CSCCTumors being more aggressive in case of immunodeﬁciency,
CSCC is classiﬁed in group 2 according to the INCa–HAS 2009 guide-
lines [9] (Expert consensus) (Table 1). Other negative clinical or
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Guideline 5
The pathology report should include: location, diameter of
tumor and of specimen, Clark level, tumor thickness (Breslow
index), perineural invasion, vascular and lymphatic emboli, dif-
ferentiation, histologic type, and resection margins laterally
and in depth (Expert consensus).
Table 1
Clinical prognostic classiﬁcation of cutaneous squamous cell carcinoma according
to  French INCa–HAS 2009 guidelines [9].
Clinical criteria Group 1: Low risk Group 2: Signiﬁcant risk
Primary vs. Recurrence Primary Recurrence
Degree of clinical
inﬁltration
Absence Adherent to deep plane
Neurologic symptoms
of invasion
No Yes
Immune status Immunocompetent Immunodeﬁcient
Diameter (according to
location)
<  10 mm in region R+ ≥ 10 mm in region R+
< 20 mm in region R− ≥ 20 mm in region R−
Note: R+ regions comprise:
• peri-oriﬁce regions and scalp;
• regions not exposed to sunlight;
• chronic dermatoses: radiation burn, burn scars, chronic inﬂammation or ulcers.
Table 2
Pathologic prognostic criteria for cutaneous squamous cell carcinoma according to
INCa–HAS 2009 guidelines [9] (Expert consensus).
Pathologic criteria Group 1: Low risk Group 2:
Signiﬁcant risk
Perineural invasion No Yes
Degree of differentiation Good Moderate to
undifferentiated
Histologic form Common, verrucous,
spindle-shaped
(outside irradiated
region), mixed or
metatypic CSCC
Desmoplastic >
mucoepidermoid >
acantholytic CSCC
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Table 3
AJCC 2010 classiﬁcation of cutaneous squamous cell carcinoma and risk factors (AJCC
Cancer Staging Manual, 2010).
TX Non-assessable primary
T0 Absence of primary
Tis In situ carcinoma
T1 Tumor ≤ 2 cm and < 2 high risk factors
T2  Tumor > 2 cm or tumor of any size with ≥ 2 high risk factors
T3 Tumor with invasion of maxillary, mandible, temporal bone or
orbit
T4 Tumor with bone invasion (axial or limbs) or perineural invasion
of skull base
Nx Non-assessable lymph nodes
N0 No regional lymph-node metastasis
N1 Lymph-node metastasis only in ipsilateral lymph-node area,
diameter ≤ 3 cm
N2 Lymph-node metastasis only in ipsilateral lymph-node area,
diameter > 3 cm but ≤ 6 cm; or multiple ipsilateral lymph-node
metastases ≤ 6 cm long axis; or multiple bilateral lymph-node
metastases ≤ 6 cm long axis
N2a Lymph-node metastasis only in ipsilateral lymph-node area,
diameter > 3 cm or ≤ 6 cm long axis
N2b Multiple ipsilateral lymph-node metastases ≤ 6 cm diameter
N2c Bilateral or contralateral lymph-node metastases ≤ 6 cm diameter
N3  Lymph-node metastasis > 6 cm diameter
Mx  Non-assessable distant metastasis
M0  No distant metastasis
M1  Distant metastasis/es
Table 4
Risk factors for primary tumor (AJCC 2010 classiﬁcation).
Breslow depth > 2 mm
Clark’s level ≥ IV
Location Ear
Differentiation Poorly differentiated or undifferentiated
Perineural invasion Yes
Guideline 6
Cutaneous squamous cell carcinoma being more aggres-
sive in immunodeﬁciency (INCa–HAS 2009 group 2: at
signiﬁcant risk of local recurrence and/or metastasis), any
CSCC in an immunodeﬁcient subject is to be discussed in a
multidisciplinary team meeting (MTM).
Management as discussed in MTM should take account of
the patient’s other clinical or histological risk factors (Expert
consensus).
Guideline 7
Clinical examination should comprise complete cutaneous
inspection (to screen for a second skin cancer), regional lymph-
node area palpation and comorbidity assessment.
Standard imaging (chest X-ray and liver ultrasound, or CT,
MRI  or PET-CT) adapted to initial AJCC stage, tumor location
and general health and comorbidity status is recommended
in case of locally advanced tumor or other risk factors (ExpertDepth (Clark’s level) and
thickness
Level ≤ III
Thickness ≤ 3 mm
Level ≥ IV
Thickness > 3 mm
istological signs are to be taken into account (Expert consensus)
Table 2).
The prognostic value of the American Joint Committee on Can-
er staging system (AJCC 2010) was conﬁrmed in immunodeﬁcient
atients [10] (level of evidence 4). The most important prognostic
actor in the AJCC classiﬁcation is tumor thickness [9,11] (level of
vidence 4). The AJCC classiﬁcation does not take direct account of
mmunodeﬁciency (Tables 3 and 4).
The lymph node region most frequently involved is the parotid,
onstituting an independent risk factor not taken account of by the
JCC classiﬁcation [12] (level of evidence 2). Parotid involvement
s classiﬁed as: P0, no parotid (only cervical) invasion; P1, ≤ 3 cm
etastasis; P2, metastasis > 3 cm and ≤ 6 cm;  P3, metastasis > 6 cm
r invasion of the base of the skull or facial nerve.
.4. Clinical and paraclinical assessment
.5. Sentinel node biopsy
.6. CSCC without palpable lymph-node involvementThe resection margin should be wide (≥ 6 mm,  or even
 10 mm),  including the peritumoral erythema, with a deep mar-
in into the subcutaneous fat, while sparing adjacent structuresconsensus).
(aponeurosis, periosteum, perichondrium) when they are neither
in contact nor invaded [9] (Expert consensus).
In case of microscopic lymph-node involvement, adjuvant radi-
ation therapy should be discussed, although its contribution in
limited microscopic involvement is unproven [9] (level of evidence
4).
In transplant patients, reduced immunodepression and conver-
sion to mTOR inhibitors is to be discussed as of CSCC onset [13]
(level of evidence 1).
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Guideline 8
The contribution of sentinel node biopsy has not been vali-
dated. It may  be implemented under certain protocols (Expert
i
(consensus).
Guideline 9
There is a severe evolutive risk of CSCC in immunodeﬁ-
ciency. Regardless of location, surgical resection with ≥ 6 mm
margins is recommended (Grade B).
Margins should be extended to 10 mm  in case of supple-
mentary clinical or histological risk factors (Grade B).
Single-step resection and closure is preferable when tech-
nically feasible (Expert consensus).
Two-step resection is recommended if complex graft or ﬂap
reconstruction is planned (Expert consensus).
If histology ﬁnds incomplete resection, surgical re-excision
is to be preferred (Expert consensus).
As palpebral surgery is difﬁcult in 2 steps, extemporaneous
examination is required (Grade C).
Mohs surgery has not been proved to be more effective
than classical techniques. It is essentially an option for tumors
of the eyelid and peri-oral region (Expert consensus).
Adjuvant radiation therapy in the resection bed is to be dis-
cussed in case of incomplete resection without possibility of
re-excision, or in case of histological features of poor progno-
sis (signs of perineural invasion, involvement of bone and/or
adjacent deep structures) (Expert consensus).
In transplant patients, reduced immunodepression and
conversion to mTOR  inhibitors is to be discussed as of ﬁrst
onset of CSCC (Grade B).
Topical treatment of the “cancerization ﬁeld” with 5-ﬂuoro-
uracile or PDT is recommended in case of peritumoral actinic
keratosis (cancerization ﬁeld treatment) (Expert consensus).
If surgical resection is not feasible, radiation therapy (exter-
nal or brachytherapy, depending on location) is an alternative.
The tumor should be analyzed on histology (Expert consen-
sus).
In non-resectable locally advanced tumor, alternatives
comprise: neoadjuvant chemotherapy, basically using cis-
platin or taxanes, EGFR inhibitors, immunotherapy (inter-
feron + retinoids), radiation therapy, and modulation of
immunosuppression (Grade C).
Guideline 10
Keratoacanthoma is difﬁcult to differentiate from squamous
cell carcinoma on histology, and should be treated surgically
(Expert consensus).
Adjuvant radiation therapy in the lymphatic drainage areas
s not recommended in CSCC without lymph node involvement
Expert consensus).
Guideline 11
Given the higher risk of recurrence during the ﬁrst 2 years,
clinical quaterly dermatological surveillance is recommended
during this period. Careful subsequent dermatological surveil-
lance is also recommended (Expert consensus).y, Head and Neck diseases 131 (2014) 121–129
4.7. Squamous cell carcinoma with regional lymph-node
involvement
Lymph-node involvement is a negative factor for survival
[14,15] (level of evidence 2–4). Extracapsular lymph-node spread
is a signiﬁcant risk factor for recurrence [16] (level of evidence 4).
The lymph-node area most frequently involved in head and neck
CSCC is the parotid.
4.7.1. Assessment
In case of palpable regional lymph-node involvement, cervico-
facial CT or MRI  assessment and CT or PET-CT remote extension
assessment should be undertaken (Expert consensus).
4.7.2. Postoperative adjuvant radiation therapy
Adjuvant radiation therapy enhances locoregional control and
survival, including in parotid involvement [14,17] (level of evidence
3–4). The usual recommended dose is around 50 Gy in 2.5–3 Gy
fractions.
Regional lymph-node area radiation therapy is recommended:
1. after cervical lymph-node dissection for palpable lymph-node
involvement [17] (level of evidence 2);
2. after positive parotidectomy for a palpable parotid mass [14,18]
(level of evidence 2).
The contribution of radiation therapy in limited microscopic
lymph-node involvement (1 node, without capsule rupture)
detected on sentinel lymph-node biopsy is unproven (Expert con-
sensus).
Guideline 12
In palpable cervical or parotid lymph-node involvement,
cervicofacial CT or MRI  should be performed, with distant
extension assessment by CT or PET-CT (Expert consensus).
In palpable cervical lymph-node involvement, complete
functional, or otherwise radical, cervical lymph-node dissec-
tion should be performed (Expert consensus).
Any suspect parotid lymphadenopathies require parotidec-
tomy + ipsilateral cervical lymph-node dissection (Grade B).
Any proven lymph-node invasion requires postoperative
adjuvant radiation therapy of the lymph-node area (Grade B).
4.8. Squamous cell carcinoma with distant metastasis
Guideline 13
In immunodepressed patients with distant metastatic
CSCC, surgery is to be considered in case of a single metas-
tasis. The decision should be made only after CT or PET-CT
extension assessment (Expert consensus).
Medical management is to be considered in inoperable
patients if performance status and comorbidity permit. Med-
ical treatment is the same as in immunocompetent subjects:
chemotherapy (essentially based on cisplatin/carboplatin),
associated interferon and retinoids, or EGFR inhibitors, alone
or in association (Grade C).
In inoperable patients, palliative radiation therapy may  be
considered (Expert consensus).
In case of regional or distant metastasis, reducing immuno-
suppression should be considered, and regular follow-up, at
least every 3 months, should be implemented (Expert consen-
sus).
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Guideline 16
Clinical examination should assess lesion diameter and
check the absence of transit lesions and regional lymph-node
involvement.
Diagnosis should be conﬁrmed on histology and immuno-
histochemistry with analysis of expression of CK20 as markerC. Bejar et al. / European Annals of Otorhinolary
. Basal cell carcinoma
Basal cell carcinoma is the most frequent form of cancer in adults
19,20] (level of evidence 2). Risk is increased 10-fold in transplant
atients and 2-fold in HIV-positive subjects. Sun exposure and clear
hototype are also major risk factors. In transplant patients, inci-
ence is increased in extracephalic sites [21] (level of evidence
).
The French prognosis classiﬁcation takes account of size, his-
ologic type, location and primary or recurrent status. Prognosis is
imilar to that in immunocompetent subjects [22] (level of evidence
).
Management: Management is similar to that for immunocompe-
ent subjects; treatment is surgical. In superﬁcial forms, imiquimod
23] (level of evidence 1) or PDT provide alternatives [24] (level of
vidence 2).
New skin carcinoma of the same type develops in 50% of cases
25] (level of evidence 2). Education, sun exposure prevention and
egular follow-up are key factors in management.
Guideline 14
As in immunocompetent subjects, basal cell carcinoma is
classiﬁed, according to the guidelines (Grade A) and to size,
histologic type, location and primary or recurrent status, as
being of good, poor or intermediate prognosis; this determines
treatment.
Treatment is generally surgical; in superﬁcial forms, how-
ever, there are possible alternatives, without risk to the graft:
imiquimod (level of evidence 1) or PDT (Grade B).
. Merkel-cell carcinoma
Merkel-cell carcinoma is a rare neuroendocrine tumor. Risk is
levated 5-fold in transplant patients and 11-fold in HIV-positive
atients [26] (level of evidence 2). Polyomavirus has been demon-
trated to be implicated [27] (level of evidence 1–3). Merkel-cell
arcinoma is aggressive, and immunodepression is a negative factor
or survival.
Location is usually in regions exposed to sunlight, including the
ace and neck (44%). Presentation is typically a single evolutive
rythematous or purple nodule, but may  also be subcutaneous.
Guideline 15
Initial imaging should be adapted to tumor stage and
comorbidities. PET-CT is sensitive in detecting lymph-node
locations and distant metastases (Grade C).
Pre-operative neuron-speciﬁc enolase (NSE) serum assay
may  be considered (Expert consensus).
The present classiﬁcation is that of the AJCC 2010: stage I,
 2 cm;  stage II, > 2 cm;  stage III, lymph-node involvement; stage IV,
emote metastasis. Survival is 50% in stage III and 9 months in stage
V [28] (level of evidence 2). Polyomavirus seems to be associated
ith better prognosis [29] (level of evidence 2).
.1. Treatment of primary tumor without palpable lymph-nodeIn all stages, extensive resection of the primary should be
erformed whenever possible. In all cases without clinical lym-
hadenopathy, it is important to resect the sentinel node to detect
nfraclinical lymph-node metastasis [30] (level of evidence 3).(Expert consensus).
Adjuvant radiation therapy provides better locoregional control
than surgery alone [31,32] (level of evidence 1).
Guideline 17
Surgery: in the absence of any palpable lymph-node, wide
resection with 2–3 cm margins should be associated to sentinel
node biopsy (Grade C).
Positive sentinel node biopsy is an indication for com-
plementary lymph-node dissection, and positive intraparotid
sentinel node biopsy for parotidectomy.
50 Gy adjuvant radiation therapy should be applied to the
tumor bed. Complementary regional radiation therapy should
also be performed in case of lymph-node involvement (Grade
A).
When extensive resection is not feasible, isolated radiation
therapy is an alternative (Grade C).
Two years’ 3-monthly surveillance is recommended, due to
the elevated risk of relapse during this period. Subsequent
dermatological follow-up should be at least annual (Expert
consensus).
There is no consensus on paraclinical surveillance. Six-
monthly imaging and serum NSE assay may  be considered
(Expert consensus).
6.2. Merkel-cell carcinoma with regional lymph-node
involvement (stage III)
Guideline 18
Adenectomy should be followed by lymph-node dissection
if lymph-node involvement is conﬁrmed. Local plus regional
adjuvant radiation therapy is recommended (Expert consen-
sus).
6.3. Merkel-cell carcinoma with remote locations (stage IV)
In remote metastasis, chemotherapy may  be undertaken as in
immunocompetent subjects [33] (Expert consensus).
The two usual protocols associate either carboplatin-
etoposide or cyclophosphamide-doxorubicin-vincristine
(Expert consensus).
7. Kaposi sarcomaKaposi sarcoma (KS) is an opportunistic tumoral proliferation
of cells derived from the lymphatic endothelium. HHV-8 infection
and immunodepression are necessary preconditions for KS.
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Table 5
The TIS classiﬁcation of the AIDS Clinical Trial Group (ACTG) of the National Institute
of  Health.
TIS classiﬁcation Good risk 0 Poor risk 1
T: Tumor Limited to Associated with
Skin and/or Edema and/or skin
ulcer
Lymph nodes and/or Non-ﬂat mouth lesions
Flat palate lesion Other visceral locations
I:  Immune system CD4 > 200/mm3 CD4 < 200/mm3
S: Systemic
symptoms
No history of
opportunistic infection
History of opportunistic
infection
No history of
oropharyngeal
candidosis
Fever or weight-loss
No fever or weight-loss Karnovsky index < 70%26 C. Bejar et al. / European Annals of Otorhinolary
.1. Post-graft KS
KS is much more frequently secondary to reactivation of pre-
raft HHV-8 infection than to primary HHV-8 infection transmitted
rom the donor [34] (level of evidence 2).
Male subjects are more often affected (2:40). Black skin and age
t transplantation seem to be associated to post-graft KS [34] (level
f evidence 2). Risk is highest in the 2 years following graft [35]
level of evidence 2).
KS has been reported in most immunosuppression regimens.
ntilymphocyte serum is a risk factor. mTOR inhibitors probably
xert a preventive effect [34,36] (level of evidence 2–4).
.2. Epidemic KS
Epidemic KS more frequently affects homosexual or bisexual
ales. The main risk factor is CD4 level.
.3. Clinical characteristics
There is cutaneo-mucosal involvement in more than 80% of
ases, with maculae forming progressively inﬁltrating erythema-
ous and purple plaques that do not disappear under vitropressure
nd tend to show an ecchymotic, hemorrhagic or pigmented aspect.
Mucosal, digestive, lymph-node and pulmonary involvement is
requent in immunodeﬁcient subjects [37] (level of evidence 4), but
he frequency of digestive and pulmonary involvement has fallen
y 50–30% since the introduction of ARTs [38,39], (level of evidence
).
.4. Diagnosis
Diagnosis should always be conﬁrmed on histology. Endothelial
ell markers such as CD31 and CD34 and the HHV-8 latency-
ssociated nuclear antigen (LANA) are positive.
.5. Initial assessment/prognostic classiﬁcations
Initial clinical assessment should include examination of the
hole cutaneo-mucosal cover and ENT and conjunctive tissue
xamination.
Guideline 19
In transplant patients, extension assessment comprises
thoraco-abdominopelvic CT and upper digestive tract
endoscopy. Bronchoscopy and lavage are recommended
in case of thoracic CT abnormalities. Colonoscopy may  be
performed, depending on the presenting symptomatology
(Expert consensus).
In epidemic KS, visceral involvement is explored by inter-
view and clinical examination as well as biological analysis
(anemia, blood in stool). Lung X-ray is systematic, without
ﬁrst-line thoraco-abdominopelvic CT (Expert consensus).Guideline 20
Opportunistic infection liable to aggravate immunodeﬁ-
ciency should be systematically screened for, as KS may
resolve when this is treated (Expert consensus).Karnovsky index > 70% Neurologic involvement,
lymphoma, etc.
7.6. Classiﬁcations
7.6.1. Post-graft KS
The Khader classiﬁcation is of limited interest, as prognosis in
post-graft KS is independent of the extent of skin involvement.
7.6.2. Epidemic KS
The TIS classiﬁcation of the AIDS Clinical Trial Group (ACTG) of
the National Institute of Health (Table 5) is of real prognostic value
(level of evidence 2).
7.7. Interest of virological examination
Serum HHV-8 assay is usually positive during KS. Elevated
viremia is signiﬁcantly associated with evolutive KS, but the pro-
gnostic value of HHV-8 viral load on PCR remains to be established.
7.8. Treatment of Kaposi sarcoma
Simply attenuating immunosuppression may stabilize or cure
KS, and is the ﬁrst-line attitude.
7.8.1. Post-graft KS
The objective is not full remission but control and conserving
graft function (Expert consensus).
Speciﬁc complementary treatment is justiﬁed only in case
of esthetic or functional concerns or life-threatening risk. Local
treatment (cryotherapy, radiation therapy) does not affect evo-
lutivity but may  be useful for limited lesions. Without awaiting
stabilization or regression of KS, after simple reduction of immuno-
suppression, calcineurin inhibitors are often replaced by mTOR
inhibitors.
In severe forms, liposomal anthracyclines (doxorubicin or
daunorubicin) may  be used in ﬁrst-line chemotherapy. In case of
failure, paclitaxel or docetaxel may  be used. Antiherpes agents have
proved disappointing [34] (level of evidence 2). Hopes have been
raised by the advent of targeted therapies: antiangiogenics, NFB
pathway inhibitors, anti-IL6, anti-STAT3.
7.8.2. Epidemic Kaposi sarcoma
ART should be initiated, and may  prove sufﬁcient, although
in some 7% of patients KS remains active despite ART and good
immunovirological control [40] (level of evidence 2).
Speciﬁc treatment may  be required, given the 3–6-month inter-
val to ART efﬁcacy or to prevent or manage an immune restoration
syndrome [41,42] (level of evidence 2).
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Guideline 21
The keystone in the management of KS after organ trans-
plantation is to minimize immunosuppression so as to control
proliferation and conserve graft function (Expert consensus).
Any concomitant opportunistic infection liable to increase
immunodeﬁciency should be systematically treated.
In severe forms, liposomal anthracyclines or taxanes may
be considered (Expert consensus).
Guideline 22
Initiation of ART is recommended when epidemic KS is
diagnosed (Grade C).
After multidisciplinary team meeting, systemic chemother-
apy (liposomal anthracycline or taxane) should be initiated in
parallel to ART in evolved KS in patients resistant to antiretrovi-
rals, especially in case of visceral (notably, pulmonary) lesions
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Guideline 23
Sentinel node biopsy is, like in immunocompetent subjects,
an option in transplant patients with melanoma (Expert con-or severe exacerbation accompanying immune restoration
(Grade B).
. Melanoma
Melanoma is more frequent in immunodeﬁcient subjects,
ncluding organ transplant, HIV-positive and lymphoma patients.
elative risk compared to the general population was  signiﬁ-
antly higher in transplant patients (RR = 2.34; 95% CI, 1.98–2.77)
han HIV-positive patients (RR = 1.24; 95% CI, 1.04–1.48) in a meta-
nalysis [43] (level of evidence 1). Prognosis is poorer than in
mmunocompetent subjects.
.1. Melanoma in transplant patients
.1.1. Melanoma transmitted by donor
Melanoma is the tumor most frequently acquired in trans-
lantation. Surgical treatment consists in removing the affected
ransplanted organ and resecting all secondary locations acces-
ible to surgery. Cessation or reduction of immunodepression is
ecommended. Speciﬁc treatment of melanoma will be discussed.
n case of remission, clinical and imaging surveillance should be
mplemented.
.1.2. Melanoma with pre-transplantation onset
In situ melanoma is not a contraindication to transplantation. In
tage I melanoma (Breslow’s depth < 1 mm,  non-ulcerated), trans-
lantation is generally allowed after 2 years’ surveillance; in stage
I, it is allowed 5 years after diagnosis, but is not recommended in
ase of lymph-node or distant metastasis [44] (Expert consensus).
entinel node biopsy can be performed as in immunocompetent
ubjects (Expert consensus).
.1.3. Melanoma with post-transplantation onset
This is the more frequent situation. Prognosis in stage T1 or T2
elanoma is similar in transplant patients and the general popula-
ion, but is less good in transplant patients with T3 or T4 melanoma
r Breslow depth > 1.5 mm or Clark’s level III, IV or V (level of evi-
ence 2).
.2. Interest of sentinel node biopsy
Sentinel node biopsy is basically of prognostic value. It may
elect patients for reduction of immunosuppression or possible
djuvant treatment within protocols. Some authors recommend
xtending indications to transplant patients in stage T1b melanoma
44] (level of evidence 4).sensus).
8.3. Treatment
Guideline 24
The treatment of melanoma in an immunodeﬁcient patient
is to be discussed in a multidisciplinary team meeting com-
prising at least a dermatologist, a surgeon specializing in
oncology and, if necessary, an infectologist or transplantation
team physician (Expert consensus).
The recommended resection margins are the same as in
immunocompetent subjects (Expert consensus).
Although the current attitude favors reducing immunosup-
pression in organ transplant patients, especially for stage ≥ II
melanoma, the interest remains to be established by prospec-
tive studies (Expert consensus).
8.4. Surveillance
The surveillance rhythm for organ transplant patients depends
on prognosis in terms of AJCC stage.
Guideline 25
The rhythm of clinical surveillance of transplant patients
with stage I melanoma is at least the same as for immuno-
competent subjects: 6-monthly for 5 years, then annually.
Transplant patients with stage II melanoma should have 3-
monthly dermatologic surveillance for 5 years, then at least
annually (Expert consensus).
8.5. Melanoma in HIV-positive patients
Time to relapse and overall survival are poorer in HIV-positive
patients than in immunocompetent subjects [45] (level of evidence
3), suggesting that those with history of melanoma should have
careful surveillance with preventive measures for those with risk
factors for skin melanoma.
In advanced unresectable melanoma requiring medical treat-
ment, antiretrovirals should be continued.
9. Lymphoma
In immunodeﬁcient subjects, lymphoma is basically type B,
often associated with EBV, and less often type T.
Skin lymphoma accounts for only 5% of lymphomas in transplant
patients [46] (level of evidence 2). They are mainly aggressive type-
B lymphomas [47,48] (level of evidence 4) and are associated with
a risk of extra-lymph-node involvement and involvement of the
transplanted organ [49] (level of evidence 2).
Data are scarce for skin lymphoma in HIV-positive patients.
The French Cutaneous Lymphoma Study Group (Groupe Franc¸ ais
d’Étude des Lymphomes Cutanés) conducted a retrospective study of
21 cases of skin lymphoma in HIV-positive patients (representing
2.6% of all registered cases in the GFELC data-base). Mycosis fun-
goides, the most frequent skin lymphoma in immunocompetent
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ubjects, was rare (3 cases). There was a high rate of type-B skin
ymphoma (10/21) and type T CD30+ and ALK1− (8/21) lymphoma
50] (level of evidence 4). To improve management, it seems impor-
ant to enter lymphomas occurring in immunodeﬁcient patients in
egistries such as that of the Groupe Franc¸ ais d’Étude des Lymphomes
utanés.
Guideline 26
Initial assessment of skin lymphoma in an immunodeﬁcient
patient should rule out secondary cutaneous location of sys-
temic lymphoma, requiring hematologic management (Expert
consensus).
Guideline 27
Reduced immunodepression in transplant patients or
change in antiretroviral treatment should be discussed in HIV-
positive patients. Hematologic tolerance for chemotherapy
requires particular surveillance in these patients. Chemother-
apy regimens are the same as for immunocompetent subjects
(Expert consensus).
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